These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 10958595)

  • 1. Phase II trial of aminocamptothecin (9-AC/DMA) in patients with advanced squamous cell head and neck cancer.
    Lad T; Rosen F; Sciortino D; Brockstein B; Keubler JP; Arietta R; Vokes E
    Invest New Drugs; 2000 Aug; 18(3):261-3. PubMed ID: 10958595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topoisomerase I inhibitors in the treatment of head and neck cancer.
    Murphy BA; Cmelak A; Burkey B; Netterville J; Shyr Y; Douglas S; Smith W
    Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):47-52. PubMed ID: 11497232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of topotecan in patients with recurrent for metastatic squamous cell carcinoma of the head and neck. A phase II Southwest Oncology Group study.
    Smith RE; Lew D; Rodriguez GI; Taylor SA; Schuller D; Ensley JF
    Invest New Drugs; 1996; 14(4):403-7. PubMed ID: 9157077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of topotecan in patients with recurrent head and neck cancer. Identification of an active new agent.
    Robert F; Soong SJ; Wheeler RH
    Am J Clin Oncol; 1997 Jun; 20(3):298-302. PubMed ID: 9167758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.
    Minami H; Lad TE; Nicholas MK; Vokes EE; Ratain MJ
    Clin Cancer Res; 1999 Jun; 5(6):1325-30. PubMed ID: 10389915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study.
    Duffaud F; Borner M; Chollet P; Vermorken JB; Bloch J; Degardin M; Rolland F; Dittrich C; Baron B; Lacombe D; Fumoleau P;
    Eur J Cancer; 2004 Dec; 40(18):2748-52. PubMed ID: 15571957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.
    Sewak S; Sorich J; O'Leary J
    Anticancer Drugs; 2006 Jun; 17(5):571-9. PubMed ID: 16702815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of rubitecan in recurrent or metastatic head and neck cancer.
    Caponigro F; Cartenì G; Droz JP; Milano A; Davis WB; Pollard P
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):209-14. PubMed ID: 17882418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of N-phosphonacetyl-L-aspartate, recombinant interferon-alpha, and fluorouracil infusion in advanced squamous cell carcinoma of the head and neck.
    Langer CJ; Schaebler D; Sauter E; DeMaria D; Johnson C; Reilly DM; Clark J; Leighton J; Aks C; Litwin S; Ridge JA
    Head Neck; 1998 Aug; 20(5):385-91. PubMed ID: 9663665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A North Central Cancer Treatment Group Phase II trial of 9-aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma.
    Pitot HC; Knost JA; Mahoney MR; Kugler J; Krook JE; Hatfield AK; Sargent DJ; Goldberg RM
    Cancer; 2000 Oct; 89(8):1699-705. PubMed ID: 11042563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I-II trial of carboplatin and 5-fluorouracil combination chemotherapy in advanced carcinoma of the head and neck.
    Forastiere AA; Natale RB; Takasugi BJ; Goren MP; Vogel WC; Kudla-Hatch V
    J Clin Oncol; 1987 Feb; 5(2):190-6. PubMed ID: 3543242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma.
    Pazdur R; Diaz-Canton E; Ballard WP; Bradof JE; Graham S; Arbuck SG; Abbruzzese JL; Winn R
    J Clin Oncol; 1997 Aug; 15(8):2905-9. PubMed ID: 9256134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390).
    Forastiere AA; Shank D; Neuberg D; Taylor SG; DeConti RC; Adams G
    Cancer; 1998 Jun; 82(11):2270-4. PubMed ID: 9610709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma.
    Adamo V; Ferraro G; Pergolizzi S; Sergi C; Laudani A; Settineri N; Alafaci E; Scimone A; Spano F; Spitaleri G
    Oral Oncol; 2004 May; 40(5):525-31. PubMed ID: 15006626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of amonafide in the treatment of patients with advanced squamous cell carcinoma of the head and the neck. An Illinois Cancer Center study.
    Rosen F; Vokes EE; Lad T; Kies M; Wade J; Kilton LJ; Blough R; French S; Mullane M; Benson AB
    Invest New Drugs; 1995; 13(3):249-52. PubMed ID: 8729954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.
    Gibson MK; Li Y; Murphy B; Hussain MH; DeConti RC; Ensley J; Forastiere AA;
    J Clin Oncol; 2005 May; 23(15):3562-7. PubMed ID: 15908667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter phase II trial of brequinar sodium in patients with advanced squamous-cell carcinoma of the head and neck.
    Urba S; Doroshow J; Cripps C; Robert F; Velez-Garcia E; Dallaire B; Adams D; Carlson R; Grillo-Lopez A; Gyves J
    Cancer Chemother Pharmacol; 1992; 31(2):167-9. PubMed ID: 1451236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II evaluation of 96-hour paclitaxel infusion in advanced (recurrent or metastatic) squamous cell carcinoma of the head and neck (E3395): a trial of the Eastern Cooperative Oncology Group.
    Langer CJ; Li Y; Jennings T; DeConti RC; Nair S; Cohen RB; Forastiere AA;
    Cancer Invest; 2004; 22(6):823-31. PubMed ID: 15641479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hr continuous infusion weekly for three weeks in metastatic colorectal carcinoma.
    Pazdur R; Medgyesy DC; Winn RJ; Dakhil SR; Moore DF; Scalzo A; Hoff PM; Arbuck SG; Abbruzzese JL
    Invest New Drugs; 1998-1999; 16(4):341-6. PubMed ID: 10426669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of m-AMSA in head and neck cancer.
    Forastiere AA; Young CW; Wittes RE
    Cancer Chemother Pharmacol; 1981; 6(2):145-6. PubMed ID: 6895486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.